96568-02-4

Basic information

• Product Name: 2,6-DICHLORO-5-FLUORONICOTINOYL CHLORIDE
• Synonyms: 2,6-DICHLORO-5-FLUORO-3-PYRIDINECARBOXYLIC ACID CHLORIDE;2,6-DICHLORO-5-FLUORO-3-PYRIDINECARBONYL CHLORIDE;2,6-DICHLORO-5-FLUORO-NICOTINIC ACID CHLORIDE;2,6-DICHLORO-5-FLUORONICOTINOYL CHLORIDE;2,6-DICHLORO-5-FLUOROPYRIDINE-3-CARBONYL CHLORIDE;2,6-DICHLOR-5-FLUORNICOTINOYLCHLORID;2,6-DICHLORO-5-FLUORO-3-PYRIDINECARBONY&;2,6-Dichloro-5-fluoronicotinoyl chloride,90%
• CAS NO: 96568-02-4
• Molecular Formula: C₆HCl₃FNO
• Molecular Weight: 228.44
• Product Categories: C6Heterocyclic Building Blocks;Halogenated Heterocycles;Heterocyclic Building Blocks;Pyridines
• Mol File: 96568-02-4.mol
• Article Data: 38

Chemical Properties

• Boiling Point: 238-239 °C(lit.)
• Flash Point: >230 °F
• Appearance: /
• Density: 1.640 g/mL at 25 °C(lit.)
• Refractive Index: n20/D >1.5720(lit.)
• Storage Temp.: 0-6°C
• PKA: -6.00±0.10(Predicted)
• CAS DataBase Reference: 2,6-DICHLORO-5-FLUORONICOTINOYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-DICHLORO-5-FLUORONICOTINOYL CHLORIDE(96568-02-4)
• EPA Substance Registry System: 2,6-DICHLORO-5-FLUORONICOTINOYL CHLORIDE(96568-02-4)

Safety Data

• Hazard Codes: C
• Statements: 34
• Safety Statements: 26-36/37/39-45
• RIDADR: UN 3265 8/PG 2
• WGK Germany: 3
• Hazardous Substances Data: 96568-02-4(Hazardous Substances Data)

Usage

Chemical Properties

clear yellow liquid

Upstream product

• 148874-68-4 methyl 2,6-dihydroxy-5-fluoronicotinate 
• 82671-03-2 ethyl 2,6-dichloro-5-fluoropyridine-3-carboxylate 
• 82671-06-5 2,6-dichloro-5-fluoro-3-pyridinecarboxylic acid 
• 113237-20-0 2,6-dichloro-5-fluoropyridine-3-carboxamide 
• 82671-02-1 2,6-dichloro-5-fluoro-pyridine-3-carbonitrile 

Downstream Products

• 100491-29-0 ethyl 7-chloro-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylate 
• 100490-99-1 ethyl-3,1-(2,4-difluoroanilino)-2-(2,6-dichloro-5-fluoronicotinyl) acrylate 
• 104051-69-6 7-(3'-aminopyrrolidinyl)-1-(2,4-difluorophenyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid hydrochloride 
• 100491-30-3 ethyl 7-chloro-1-(4-fluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylate 
• 100426-74-2 7-Chloro-6-fluoro-4-oxo-1-phenyl-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid ethyl ester 
• 100426-73-1 (Z)-2-(2,6-Dichloro-5-fluoro-pyridine-3-carbonyl)-3-phenylamino-acrylic acid ethyl ester 
• 100491-00-7 ethyl 3-p-fluoroanilino-2-(2,6-dichloro-5-fluoronicotinyl)acrylate 
• 104051-61-8 6-Fluoro-4-oxo-1-phenyl-7-piperazin-1-yl-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid ethyl ester 
• 100491-95-0 6-Fluoro-1-(4-fluoro-phenyl)-7-(3-hydroxy-pyrrolidin-1-yl)-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid ethyl ester 
• 104069-95-6 6-Fluoro-1-(4-fluoro-phenyl)-4-oxo-7-piperazin-1-yl-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid ethyl ester 
• 100546-84-7 ethyl 1-p-fluorophenyl-6-fluoro-7-(3-methyl-1-piperazinyl)-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylate 
• 100491-52-9 6-Fluoro-1-(4-fluoro-phenyl)-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid ethyl ester 
• 104051-62-9 ethyl 1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylate 
• 100492-07-7 1-(2,4-Difluoro-phenyl)-6-fluoro-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid ethyl ester 

Relevant articles and documents

Discovery of the decarboxylative biaise reaction and its application to the efficient synthesis of ethyl 2,6-dichloro-5-fluoronicotinoylacetate

An efficient synthesis of 2,6-dichloro-5-fluoronicotinoylacetate (1) has been accomplished in a single step using the unprecedented decarboxylative Biaise reaction of 3-cyano-2,6-dichloro-5-fluoropyridine (4) with potassium ethyl malonate in the presence of zinc chloride.

Heterocyclic compound and application thereof

The invention relates to a heterocyclic compound and application thereof. The compound is a compound represented by a formula I, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a tautomer thereof, or a hydrate thereof, or a solvate thereof, or a metabolite thereof, or a prodrug thereof, and R1-R2 and A, E, L and K groups are defined in the specification. The compound provided by the invention can be used for preparing medicines for treating and/or preventing cancers.

COVALENT RAS INHIBITORS AND USES THEREOF

The disclosure features compounds, or pharmaceutically acceptable salts thereof, alone and in combination with other therapeutic agents, pharmaceutical compositions, and protein conjugates thereof, capable of modulating biological processes including Ras, and their uses in the treatment of cancers.